Ashwagandha has become one of the most widely used adaptogens on the market, taken daily by people chasing lower cortisol, better sleep, and a calmer nervous system, usually with little more scrutiny than a multivitamin gets. That popularity is exactly why a July 2026 systematic review published in The Egyptian Journal of Internal Medicine is worth reading carefully rather than reacting to. The researchers were not running a new clinical trial — they were pulling together every documented case report of ashwagandha-associated liver injury they could find in the medical literature, and organizing what had, until now, existed only as scattered individual reports. Understanding what they actually found, and what they did not find, matters more than any headline built around the word “liver.”
What the Review Actually Looked At
Following PRISMA systematic-review methodology, the researchers searched PubMed, Medline, Google Scholar, ScienceDirect, and Web of Science, and identified 19 studies containing a combined 26 documented cases of ashwagandha-associated liver injury. That is the entire dataset the review is built on — not 26 cases discovered in a single hospital or a single week, but 26 cases collected from published medical literature across however many years those studies span. The people affected had a mean age of 37.8 years (plus or minus 15.1), and were 53.9% male (16 of 26) versus 46.1% female (12 of 26) — a fairly even split with a modest lean toward men. Reported daily doses ranged widely, from 450 mg up to 2,100 mg, taken in the form of gummies, capsules, powders, and syrups, and the duration of use before injury appeared ranged from as little as one month to more than a year. In most cases, symptoms did not show up right away — onset was typically delayed, emerging weeks to months after someone started taking ashwagandha, which is part of why a supplement someone has been using for a while without issue does not automatically rule it out as a cause if something changes later.
What the Warning Signs Actually Looked Like
One of the more useful parts of a case-report review like this is that it tells you what to actually watch for, in plain terms, rather than a vague warning to “be careful.” Across the 26 documented cases, the symptoms broke down like this:
- Jaundice (yellowing of the skin or eyes) — 88.5% of cases, by far the most common sign
- Itching, or pruritus — 72.9% of cases
- Nausea — 38.5% of cases
- Dark urine and abdominal pain — 26.9% of cases
- Unintended weight loss — 11.5% of cases
On the lab side, some of the affected cases showed striking numbers — ALT levels as high as 3,400 IU/L, AST as high as 2,500 U/L, and total bilirubin as high as 31.5 mg/dL — with injury patterns described as hepatocellular, cholestatic, or mixed, depending on the case. Those are not normal, low-grade lab fluctuations; they reflect real, significant liver stress in the people who experienced them. The practical takeaway is not to memorize lab thresholds, but to know that jaundice, persistent itching, dark urine, and abdominal pain are the cluster of symptoms this review associates most consistently with the injury pattern, and none of them should be shrugged off as unrelated to a supplement someone is currently taking.
Why This Is Not Simply a “More Ashwagandha, More Risk” Story
It would be easy to assume that higher doses or longer use drove the injuries, but the review specifically did not find a clear dose-response relationship. In other words, someone taking 450 mg was not obviously safer than someone taking 2,100 mg, and there was no consistent pattern where risk climbed neatly alongside dose or duration. That is an important, and somewhat unsettling, nuance: it points toward an idiosyncratic reaction — an unpredictable response in a susceptible individual, rather than a straightforward toxic effect where more exposure reliably equals more damage. This is precisely why nobody should walk away from this review thinking a low dose is inherently safe or that a high dose is definitively the culprit. Idiosyncratic drug- and supplement-induced liver injury shows up this way across many substances, not just ashwagandha, and it is one of the hardest patterns to predict in advance for any individual person.
Putting 26 Cases in Proportion
Ashwagandha is one of the most commonly used herbal supplements in the world, taken by an enormous and growing number of people every single day, across gummies, capsules, powders, and drink mixes sold everywhere from pharmacies to grocery stores. Against that backdrop, 26 documented cases collected across 19 studies in the global medical literature is a small number. This review is a real, legitimate safety signal worth taking seriously — it is not a reason to conclude ashwagandha is broadly dangerous, and it is not evidence that the general population taking it should expect liver problems. The honest reading is that this appears to be a rare, idiosyncratic event in susceptible individuals, documented seriously enough that clinicians and researchers now have a clearer picture of what it looks like when it happens. The outcomes reported were reassuring in most respects — stopping ashwagandha led to recovery in most of the documented cases. But the review is also clear that outcomes were not uniformly mild: some cases were severe enough to require intensive care, and some required liver transplantation. Both things are true at once: this is rare, and when it does happen, it can be serious.
The researchers also noted a male predominance among the case reports and speculated this could relate to differences in hepatic enzyme expression or usage patterns between men and women. That is worth mentioning as a possible association the researchers flagged, not a proven cause — the review itself frames it as a hypothesis for future research, not a settled explanation.
FAQ
Does this mean ashwagandha is unsafe?
No. This review documents 26 case reports of liver injury against the backdrop of a supplement used by a very large number of people worldwide. It is a genuine safety signal that deserves attention, not evidence that ashwagandha is broadly dangerous for the general population.
Is a lower dose of ashwagandha safer?
Not necessarily, according to this review. Because no clear dose-response relationship was found, lower doses were not reliably associated with lower risk, and higher doses were not reliably associated with higher risk. This points to an idiosyncratic reaction in susceptible individuals rather than a simple dose-driven effect, which is why this article does not recommend any specific “safe” amount.
What should I do if I am currently taking ashwagandha?
This is not a reason to panic or stop cold on your own. It is a good reason to know the warning signs described in this review — yellowing of the skin or eyes, dark urine, itching, and abdominal pain — and to stop taking it and contact a doctor promptly if any of them appear. People with existing liver conditions, people who drink alcohol regularly, or anyone taking other medications processed by the liver should talk to a doctor before starting ashwagandha in the first place.
This article is general education based on a published case-report review, not medical advice, a diagnostic tool, or a recommendation to start or stop any supplement or medication. If you have questions about your own liver health, current medications, alcohol use, or whether ashwagandha is appropriate for you, talk to a doctor or pharmacist who knows your full health history.
Final Thoughts
The 2026 review does not turn ashwagandha into a supplement to fear, but it does turn a handful of scattered case reports into a documented, citable pattern that clinicians and consumers can actually reference. Knowing the warning signs — jaundice, dark urine, itching, abdominal pain — and knowing that risk here is not simply a matter of dose, is more useful than either dismissing the finding or overreacting to it.
For more grounded, evidence-first coverage of the supplements and treatments actually worth your attention, visit gemifys.com for more wellness content like this.
